Report Overview
The US AI in Diagnostics Market is forecast to grow at a CAGR of 27.9%, reaching USD 4.8 billion in 2031 from USD 1.4 billion in 2026.
Highlights:
- 1Accelerated clinical adoption and rapid internalization signal a strong, verifiable surge in end-user demand for AI-based diagnostics.
- 2The US Food and Drug Administration is actively adapting its regulatory framework to address software as a medical device that utilizes evolving AI algorithms, demonstrating a formal process to integrate these dynamic tools safely into clinical practice.
- 3The medical industry imperative toward integrating deep learning-based cancer screening and diagnostic tools directly into large-scale diagnostic imaging networks, vertically integrating AI into the service delivery model.
- 4The primary area of opportunity identified of US physicians for AI adoption is the reduction of administrative and documentation burdens, which directly translates into demand for AI solutions that streamline clinical workflow rather than solely focusing on pure diagnostic assistance.
The US AI in Diagnostics market is undergoing a profound structural shift, moving from a niche technology to an indispensable component of clinical workflow across high-volume diagnostic segments. This transition is predicated on the dual pressures of managing escalating chronic disease prevalence and mitigating critical workforce shortages, particularly among specialists like radiologists. The commercial focus is firmly on delivering verified, regulatory-cleared software that seamlessly integrates into existing Picture Archiving and Communication Systems (PACS) and Electronic Health Records (EHRs).
US AI in Diagnostics Market Analysis
Growth Drivers
The primary catalyst propelling market expansion is the critical shortage of specialist physicians, directly increasing demand for automated assistance. With significant percentages of radiologist job searches remaining unfilled, the industry requires AI to act as a force multiplier, ranking cases and identifying anomalies to offload high-volume workload from human analysts. This demand is further amplified by the exponential growth in medical imaging data (CT, MRI, X-ray), for which advanced Deep Learning and Natural Language Processing algorithms are necessary to manage and interpret, preventing diagnostic backlogs.
The growing emphasis on early and precise disease detection, particularly for conditions like cancer and neurological disorders, creates direct demand for AI to identify subtle patterns in images and genomic data earlier than traditional human observation, thereby improving clinical outcomes and resource utilization.
Challenges and Opportunities
A significant constraint on the market is the fragmentation and non-interoperability of data, which creates an obstacle for seamlessly integrating new AI tools with established EHR and imaging platforms. This friction decreases demand by raising implementation costs and workflow disruption. Conversely, a major opportunity lies in the application of Explainable AI (XAI), which increases clinician trust and, consequently, adoption rates by providing transparency into the AI's decision-making process. Furthermore, the rising need for AI accelerators and high-performance graphics processing Units (GPUs) at the point of care drives demand for hardware components that can support real-time inference, opening a strategic opportunity for hardware manufacturers within this primarily software-driven market.
Raw Material and Pricing Analysis
The US AI In Diagnostics market is predominantly a Software as a Medical Device (SaMD) and service-based offering. It is categorized as an intangible asset; therefore, a raw material and pricing analysis focused on physical components (e.g., chemicals, electronics, materials) is not applicable to this market. The primary cost drivers for this market reside in data acquisition, algorithm training (computational costs and specialist data scientist salaries), regulatory compliance processes, and intellectual property development, rather than physical supply chain costs.
Supply Chain Analysis
The global supply chain for AI in diagnostics is primarily a digital data and software-centric value chain, rather than a physical one, built on layers of dependencies. The key production hubs are concentrated in established global technology clusters—specifically the US, China, and Western Europe, where the talent pool for machine learning engineers and clinical data scientists resides. Logistical complexities revolve around data sovereignty, security, and the clinical annotation of massive, diverse datasets, not the transport of physical goods. The market exhibits a heavy dependency on semiconductor manufacturers (e.g., NVIDIA, AMD) for high-performance computing hardware (GPUs/accelerators) essential for training and running complex deep learning models in data centers and at the edge. Geopolitical factors, such as tariffs on specific high-performance computing hardware from China, would increase the capital expenditure for AI model training and deployment. This elevated cost would be passed on to US diagnostic providers, acting as a frictional headwind that restrains the rapid adoption and scaling of AI services by smaller Diagnostic Laboratories and Clinics.
Government Regulations
Key government regulations in the US primarily govern data handling and device approval, shaping the market structure and directly impacting the time-to-market and compliance costs for manufacturers.
Jurisdiction | Key Regulation / Agency | Market Impact Analysis |
|---|---|---|
United States | Food and Drug Administration (FDA): Center for Devices and Radiological Health (CDRH) | FDA 510(k) and De Novo clearances for AI-enabled SaMD validate clinical utility and safety, directly enabling market entry and increasing clinician trust, which accelerates demand. Focus is on Good Machine Learning Practices (GMLP). |
United States | Health Insurance Portability and Accountability Act (HIPAA) | Mandates stringent rules for the security and privacy of Protected Health Information (PHI). This restricts the ease of data sharing and aggregation for model training, posing a significant logistical and legal challenge that increases the cost of data acquisition and model development, thus acting as a constraint on the supply side. |
US AI in Diagnostics Market Segment Analysis
By Diagnostic Type: Radiology
The Radiology segment represents the most mature and dominant application area in the US AI in Diagnostics market, driven by quantifiable metrics of demand. The confluence of a chronic radiologist shortage and an unrelenting increase in imaging volume (CT, MRI, X-ray) creates an acute need for AI to maintain operational efficiency. This environment propels demand for AI to automate non-interpretive tasks, such as protocoling studies and optimizing hanging protocols, and high-impact triage functions, such as flagging critical findings in real time to reduce turnaround times in emergency settings. Furthermore, the integration of AI models, like those for breast density assessment and lesion characterization, directly contributes to value-based care initiatives by demonstrably improving diagnostic accuracy and reducing diagnostic error rates, making these tools an operational imperative for US hospitals and imaging centers.
By End-User: Hospitals and Clinics
Hospitals and Clinics constitute the largest end-user segment due to their high patient volumes, complexity of cases, and mandate to improve both clinical outcomes and financial performance. Demand from this segment is specifically driven by the need for AI to optimize clinical workflow and address administrative burnout. Tools that can automate documentation of billing codes, generate chart summaries, and assist in creating discharge instructions are in high demand as they directly reduce non-clinical staff burdens. Moreover, large hospital systems are focused on integrating AI into multi-modality diagnostic pathways across Radiology, Cardiology, and Oncology to achieve greater standardization of care. Their investment capacity allows for the adoption of comprehensive enterprise-level AI platforms (Software) that are seamlessly integrated with EHRs, contrasting with the more fragmented adoption patterns of smaller clinics.
US AI in Diagnostics Market Competitive Environment and Analysis
The US AI in Diagnostics market exhibits a distinct competitive structure, dominated by two categories of players: legacy, multinational medical technology conglomerates and innovative, agile pure-play AI software developers.
Siemens Healthineers AG- Siemens Healthineers holds a strategic position by embedding AI directly into its vast installed base of diagnostic imaging hardware (MRI, CT, X-ray). The company's strategy, anchored by its AI-Rad Companion portfolio, is to deliver a seamlessly integrated, multi-modality AI solution.
IBM Corporation- IBM’s positioning is centered on the IBM Watson Health platform (specifically related to its AI and data management expertise, although parts of the health division were divested) and its enterprise-level data and AI services. The company focuses on the high-level infrastructure required for AI implementation, including data governance, security, and cloud deployment, utilizing its WatsonX suite of AI tools.
US AI in Diagnostics Market Recent Developments
May 2026: Roche agreed to acquire U.S.-based PathAI to strengthen AI-powered digital pathology diagnostics, expanding automated cancer diagnostic workflows and AI-enabled companion diagnostic algorithm development capabilities.
March 2026: Perimeter Medical Imaging AI announced FDA approval for its AI-enabled “Claire” imaging technology, becoming the first FDA-approved AI device supporting real-time breast cancer surgery diagnostics and margin assessment.
March 2026: Mosaic Clinical Technologies announced FDA Breakthrough Device Designation for Cognita, its generative AI radiology diagnostic model designed to improve imaging workflow efficiency and radiology diagnostic capacity management.
August 2025: DeepHealth, Inc. (a RadNet Subsidiary) FDA Clearance DeepHealth received FDA 510(k) clearance for TechLive™, a remote scanning solution. This software enables centralized operation and supervision of MR, CT, PET/CT, and Ultrasound procedures from a remote location.
US AI in Diagnostics Market Scope
| Report Metric | Details |
|---|---|
| Total Market Size in 2026 | USD 1.4 billion |
| Total Market Size in 2031 | USD 4.8 billion |
| Forecast Unit | Billion |
| Growth Rate | 27.9% |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Component, Diagnostic Type, Application, End-User |
| Companies |
|
Market Segmentation
By Component
By Diagnostic Type
By Application
By End User
Table of Contents
1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. US AI IN DIAGNOSTICS MARKET BY COMPONENT
5.1. Introduction
5.2. Software
5.3. Hardware
6. US AI IN DIAGNOSTICS MARKET BY DIAGNOSTIC TYPE
6.1. Introduction
6.2. Radiology
6.3. Pathology
6.4. Cardiology
6.5. Oncology
6.6. Neurology
6.7. Others
7. US AI IN DIAGNOSTICS MARKET BY APPLICATION
7.1. Introduction
7.2. Disease Detection
7.3. Image Analysis
7.4. Risk Assessment
7.5. Predictive Analysis
7.6. Others
8. US AI IN DIAGNOSTICS MARKET BY END USER
8.1. Introduction
8.2. Hospitals And Clinics
8.3. Diagnostic Laboratories
8.4. Research Institutions
8.5. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. IBM Corporation
10.2. General Electric (GE) Company
10.3. Siemens Healthineers AG
10.4. Aidoc Medical Ltd.
10.5. Zebra Medical Vision Ltd.
10.6. Butterfly Network, Inc.
10.7. Viz.Ai, Inc.
10.8. Imagen Technologies, Inc.
10.9. Alivecor, Inc.
10.10. Pathai, Inc.
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES
Navigate
Trusted by the world's leading organizations
